Oculgen Biomedical Technology has closed a USD 30 million Series B financing round. The proceeds will accelerate the global Phase II clinical development of the company's lead asset, OCUL101, a first-in-class bispecific antibody (BsAb) targeting both VEGF and complement C5 for major retinal diseases. The candidate is designed to treat neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME) and geographic atrophy (GA), addressing a significant unmet need for millions of patients worldwide.

In a completed Phase Ib single ascending dose study, OCUL101 demonstrated a favourable safety profile with no dose-limiting toxicities or vision-threatening events. A single injection provided visual acuity and anatomical improvements sustained for 12 weeks, suggesting the potential for a less frequent dosing regimen compared to current anti-VEGF therapies. Oculgen plans to initiate a Phase II trial for GA in China in January 2026 and advance parallel Phase II studies in both the US and China, supported by the new funding.

PharmCube's NextBiopharm® database lists only 50 companies developing a total of 52 BsAb projects in ophthalmology. Click here to request a free trial for NextBiopharm®.